ALLR vs DRMA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 18, 2026

ALLR

38.4
AI Score
VS
DRMA Wins

DRMA

39.7
AI Score

Investment Advisor Scores

ALLR

38score
Recommendation
SELL

DRMA

40score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ALLR DRMA Winner
Net Income -6.16M -4.81M DRMA
Operating Income -5.36M -4.94M DRMA
ROE -174.1% -138.0% DRMA
ROA -19.2% -90.5% ALLR
Total Assets 32.12M 5.32M ALLR
Cash 16.98M 4.41M ALLR
Current Ratio 1.11 3.40 DRMA
Free Cash Flow -7.12M -5.01M DRMA

Relative Price Performance (Last 90 Days)

ALLR 1M: +17.2% · 3M: -13.9% DRMA 1M: +15.5% · 3M: +17.3%

Current Technical Phase

ALLR

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 61.0 · Price: $1.43

DRMA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.8% over 20 days), RSI 59

RSI (14): 58.8 · Price: $1.46

Fundamentals Snapshot

Metric ALLR DRMA
Market Cap
Forward P/E -1.5 -1.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 1.0%
Operating Margin -107.5% 0.0%
EPS -0.83 -4.32
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, DRMA is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.